Potential use of monoclonal antibodies in the diagnostic distinction of gynecomastia from breast carcinoma in men

M. Mottolese, G. Bigotti, A. Coli, C. Vitucci, P. G. Natali

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Immunohistochemical (IHC) assays using the monoclonal antibodies (MoAbs) B72.3 and B6.2, recognizing two distinct and independently expressed breast tumor-associated antigens (BTAAs), recently have been shown to significantly improve the accuracy of cytodiagnosis of breast nodules by fine-needle aspiration (FNA). To evaluate whether the same method may be useful diagnostically in distinguishing gynecomastia from breast cancer in men, a retrospective avidin-biotin immunoperoxidase assay study was performed on 50 cases of gynecomastia and 30 cases of breast carcinoma in men, using a panel of five MoAbs known to recognize different BTAAs. The results of this study demonstrated that MoAbs B1.1, HMFG2, and MBr1 displayed a strong reactivity with gynecomastia and carcinoma, but MoAbs B72.3 and B6.2 separated benign and malignant lesions in a high percentage of cases. When used in combination, the latter two reagents reacted with 96% of the carcinomas that were analyzed but labeled only 67% of gynecomastia cases. Thus, the conjoint use of these two reagents may enhance the use of FNA biopsy as a valuable tool in the presurgical diagnosis of breast nodules in men.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalAmerican Journal of Clinical Pathology
Volume96
Issue number2
Publication statusPublished - 1991

Fingerprint

Gynecomastia
Monoclonal Antibodies
Breast Neoplasms
Neoplasm Antigens
Fine Needle Biopsy
Breast
Cytodiagnosis
Carcinoma
Avidin
Biotin
B72.3 antibody

Keywords

  • Breast carcinoma
  • Fine-needle aspiration
  • Gynecomastia
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Potential use of monoclonal antibodies in the diagnostic distinction of gynecomastia from breast carcinoma in men. / Mottolese, M.; Bigotti, G.; Coli, A.; Vitucci, C.; Natali, P. G.

In: American Journal of Clinical Pathology, Vol. 96, No. 2, 1991, p. 233-237.

Research output: Contribution to journalArticle

@article{c7ee9b7b0ac74bd1ae0e6e5e403df241,
title = "Potential use of monoclonal antibodies in the diagnostic distinction of gynecomastia from breast carcinoma in men",
abstract = "Immunohistochemical (IHC) assays using the monoclonal antibodies (MoAbs) B72.3 and B6.2, recognizing two distinct and independently expressed breast tumor-associated antigens (BTAAs), recently have been shown to significantly improve the accuracy of cytodiagnosis of breast nodules by fine-needle aspiration (FNA). To evaluate whether the same method may be useful diagnostically in distinguishing gynecomastia from breast cancer in men, a retrospective avidin-biotin immunoperoxidase assay study was performed on 50 cases of gynecomastia and 30 cases of breast carcinoma in men, using a panel of five MoAbs known to recognize different BTAAs. The results of this study demonstrated that MoAbs B1.1, HMFG2, and MBr1 displayed a strong reactivity with gynecomastia and carcinoma, but MoAbs B72.3 and B6.2 separated benign and malignant lesions in a high percentage of cases. When used in combination, the latter two reagents reacted with 96{\%} of the carcinomas that were analyzed but labeled only 67{\%} of gynecomastia cases. Thus, the conjoint use of these two reagents may enhance the use of FNA biopsy as a valuable tool in the presurgical diagnosis of breast nodules in men.",
keywords = "Breast carcinoma, Fine-needle aspiration, Gynecomastia, Monoclonal antibodies",
author = "M. Mottolese and G. Bigotti and A. Coli and C. Vitucci and Natali, {P. G.}",
year = "1991",
language = "English",
volume = "96",
pages = "233--237",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Potential use of monoclonal antibodies in the diagnostic distinction of gynecomastia from breast carcinoma in men

AU - Mottolese, M.

AU - Bigotti, G.

AU - Coli, A.

AU - Vitucci, C.

AU - Natali, P. G.

PY - 1991

Y1 - 1991

N2 - Immunohistochemical (IHC) assays using the monoclonal antibodies (MoAbs) B72.3 and B6.2, recognizing two distinct and independently expressed breast tumor-associated antigens (BTAAs), recently have been shown to significantly improve the accuracy of cytodiagnosis of breast nodules by fine-needle aspiration (FNA). To evaluate whether the same method may be useful diagnostically in distinguishing gynecomastia from breast cancer in men, a retrospective avidin-biotin immunoperoxidase assay study was performed on 50 cases of gynecomastia and 30 cases of breast carcinoma in men, using a panel of five MoAbs known to recognize different BTAAs. The results of this study demonstrated that MoAbs B1.1, HMFG2, and MBr1 displayed a strong reactivity with gynecomastia and carcinoma, but MoAbs B72.3 and B6.2 separated benign and malignant lesions in a high percentage of cases. When used in combination, the latter two reagents reacted with 96% of the carcinomas that were analyzed but labeled only 67% of gynecomastia cases. Thus, the conjoint use of these two reagents may enhance the use of FNA biopsy as a valuable tool in the presurgical diagnosis of breast nodules in men.

AB - Immunohistochemical (IHC) assays using the monoclonal antibodies (MoAbs) B72.3 and B6.2, recognizing two distinct and independently expressed breast tumor-associated antigens (BTAAs), recently have been shown to significantly improve the accuracy of cytodiagnosis of breast nodules by fine-needle aspiration (FNA). To evaluate whether the same method may be useful diagnostically in distinguishing gynecomastia from breast cancer in men, a retrospective avidin-biotin immunoperoxidase assay study was performed on 50 cases of gynecomastia and 30 cases of breast carcinoma in men, using a panel of five MoAbs known to recognize different BTAAs. The results of this study demonstrated that MoAbs B1.1, HMFG2, and MBr1 displayed a strong reactivity with gynecomastia and carcinoma, but MoAbs B72.3 and B6.2 separated benign and malignant lesions in a high percentage of cases. When used in combination, the latter two reagents reacted with 96% of the carcinomas that were analyzed but labeled only 67% of gynecomastia cases. Thus, the conjoint use of these two reagents may enhance the use of FNA biopsy as a valuable tool in the presurgical diagnosis of breast nodules in men.

KW - Breast carcinoma

KW - Fine-needle aspiration

KW - Gynecomastia

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=0026320477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026320477&partnerID=8YFLogxK

M3 - Article

VL - 96

SP - 233

EP - 237

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -